0001213900-22-032242.txt : 20220610 0001213900-22-032242.hdr.sgml : 20220610 20220610161520 ACCESSION NUMBER: 0001213900-22-032242 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20220607 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220610 DATE AS OF CHANGE: 20220610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AIkido Pharma Inc. CENTRAL INDEX KEY: 0000012239 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 520849320 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-05576 FILM NUMBER: 221009055 BUSINESS ADDRESS: STREET 1: ONE ROCKEFELLER PLAZA, 11TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 347-321-7646 MAIL ADDRESS: STREET 1: ONE ROCKEFELLER PLAZA, 11TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 FORMER COMPANY: FORMER CONFORMED NAME: Aikido Pharma Inc. DATE OF NAME CHANGE: 20200317 FORMER COMPANY: FORMER CONFORMED NAME: SPHERIX INC DATE OF NAME CHANGE: 20010815 FORMER COMPANY: FORMER CONFORMED NAME: BIOSPHERICS INC DATE OF NAME CHANGE: 19920703 8-K 1 ea161453-8k_aikido.htm CURRENT REPORT
0000012239 false --12-31 0000012239 2022-06-07 2022-06-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 7, 2022

 

AIKIDO PHARMA INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-05576   52-0849320

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(I.R.S. Employer

Identification No.)

 

One Rockefeller Plaza, 11th Floor, New York, NY   10020
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (703) 992-9325

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   AIKI   The Nasdaq Capital Market

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 7, 2022, the board of directors (the “Board”) of Aikido Pharma, Inc. (the “Company”) appointed Soo Yu to serve as a member of the Board.

 

Ms. Yu is the wife of Kyle Wool, a board member and shareholder of the Company, and the president of Revere Securities, a corporation which the Company has previously used to strategically manage and build its investment processes. There is no arrangement or understanding between Ms. Yu and any other persons pursuant to Ms. Yu’s appointment as director, and there are no related party transactions involving Ms. Yu that are reportable under Item 404(a) of Regulation S-K. There are no material plans, contracts, or arrangements to which Ms. Yu is a party to or in which she participates, nor have there been any material amendments to any plan, contract, or arrangement by virtue of Ms. Yu’s appointment.

 

On June 10, 2022, the Company issued a press release with respect to Ms. Yu’s appointment as described herein. A copy of the press release is attached hereto as Exhibit 99.1.

 

The following is certain biographical information regarding Ms. Yu:

 

Ms. Yu, age 51, is a licensed financial advisor and the current Managing Director of International Private Client Services for Revere Securities. With more than a decade of experience working in financial services, Ms. Yu focuses on international business development and the cultivation of overseas client banking relationships.

 

A naturalized U.S. Citizen originally from South Korea, Ms. Yu brings significant expertise in Asian markets and expansive global reach through her connectivity with international contracts. Ms. Yu earned her B.A. in Fine Arts from the Fashion Institute of Technology in 1996 and studied at the University of Nottingham and the Paris Fashion Institute. She holds Series 7 and Series 66 designations and her real estate license. Previously, Ms. Yu maintained her Series 79 and 24 licenses.

 

Ms. Yu actively supports several nonprofit organizations, including philanthropies committed to improving the lives of children and the elderly, as well as sustainability.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On June 7, 2022, the Company effected a seventeen-for-one (17-for-1) reverse stock split of its class of common stock, par value $0.0001 per share (the “Reverse Stock Split”). On June 2, 2022, The Company filed a Certificate of Amendment (the “Amendment”) of its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Reverse Stock Split.

 

As a result of the Reverse Stock Split, every seventeen (17) shares of the Company’s common stock issued and outstanding were combined into one (1) share of common stock issued and outstanding, with no change to the par value of $0.0001 per share. This reduced the Company’s then-outstanding common stock from approximately 89,294,446 million shares to approximately 5,252,555 million shares. Fractional shares resulting from the reverse stock split were rounded down to the nearest whole share, and all then-currently issued shares of common stock held by a shareholder was aggregated for the purpose of determining whether the reverse stock split would result in the issuance of a fractional share. The Company’s post-Reverse Stock Split common stock began trading on June 7, 2022 with a new CUSIP number of 0088753043.

 

1

 

 

The Company's transfer agent, Continental Stock Transfer & Trust Company will provide stockholders of record holding certificates representing pre-split shares of the Company's common stock as of the effective date, a letter of transmittal providing instructions for the exchange of shares. Registered stockholders holding pre-split shares of the Company's common stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split, subject to such broker's particular processes, and will not be required to take any action in connection with the Reverse Stock Split.

 

On June 3, 2022, the Company issued a press release with respect to the Reverse Stock Split described herein. A copy of the press release is attached hereto as Exhibit 99.2.

 

A copy of the Amendment is filed as Exhibit 3.1 and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

3.1  Certificate of Amendment to Amended and Restated Articles of Incorporation of AIkido Inc. filed with the Delaware Secretary of State on June 2, 2022, and effective at 12:01 a.m. on June 7, 2022.
99.1  Press Release Announcing the Appointment of Soo Yu to the AIkido Inc., Board of Directors.
99.2  Press Release Announcing the Reverse Stock Split of AIkido Inc. dated June 3, 2022.
104  Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AIKIDO PHARMA INC.
     
  By: /s/ Anthony Hayes
  Name: Anthony Hayes
  Title: Chief Executive Officer
     
Dated: June 10, 2022    

 

 

3

 

 

EX-3.1 2 ea161453ex3-1_aikido.htm CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED ARTICLES OF INCORPORATION OF AIKIDO INC. FILED WITH THE DELAWARE SECRETARY OF STATE ON JUNE 2, 2022, AND EFFECTIVE AT 12:01 A.M. ON JUNE 7, 2022

Exhibit 3.1

 

  Delaware Page 1
  The First State  

 

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “AIKIDO PHARMA INC.”, FILED IN THIS OFFICE ON THE SECOND DAY OF JUNE, A.D. 2022, AT 5:32 O’CLOCK P.M.

 

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF AMENDMENT IS THE SEVENTH DAY OF JUNE, A.D. 2022 AT 12:01 O’CLOCK P.M.

 

     

2296558 8100

SR# 20222605008

Authentication: 203583713

Date: 06-02-22

 

You may verify this certificate online at corp.delaware.gov/authver.shtml

 

 

 

 

CERTIFICATE OF AMENDMENT
OF THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF

AIKIDO PHARMA INC.

 

Alkido Pharma Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify:

 

FIRST: That at a meeting of the Board of Directors of the Corporation, resolutions were duly adopted setting forth a proposed amendment of the Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable. The resolution setting forth the proposed amendment is as follows:

 

RESOLVED, effective as of 12:01 a.m., Eastern time, on June 7, 2022 (the “Effective Time”), that the Amended and Restated Certificate of Incorporation of the Corporation be amended by changing Clause “A” of the Article thereof numbered “FOURTH” so that, as amended, said Clause “A” of the Article thereof numbered “FOURTH” shall be and read as follows:

 

“A. The total number of shares of stock of all classes that the Corporation shall have authority to issue is One Hundred Fifty Million (150,000,000) shares, consisting of One Hundred Million (100,000,000) shares of common stock, par value$0.0001 per share (the “Common Stock”), and Fifty Million (50,000,000) shares of preferred stock, par value $0.0001 per share (the “Preferred Stock”).

 

Effective as of the Effective Time, each seventeen 17 shares of common stock, par value $0.0001 per share (the “Old Common Stock”), issued and outstanding immediately before the Effective Date, shall be and hereby is, reclassified as and changed into one (1) share of common stock, par value $0.0001 per share (the “New Common Stock”). Each outstanding stock certificate which immediately before the Effective Date represented one or more shares of Old Common Stock shall thereafter, automatically and without the necessity of surrendering the same for exchange, represent the number of whole shares of New Common Stock determined by multiplying the number of shares of Old Common Stock represented by such certificate immediately prior to the Effective Date by one-seventeenth 1/17, and shares of Old Common Stock held in uncertificated form shall be treated in the same manner. No fractional shares shall be issued in connection therewith. Stockholders who would otherwise be entitled to receive fractional share interests of Common Stock shall instead receive a cash payment equal to the fraction multiplied by the closing sales price of our Common Stock as of the date of the Effective Time.”

 

SECOND: That thereafter, pursuant to resolution of its Board of Directors, the annual meeting of the stockholders of the Corporation was duly called and held upon notice in accordance with Section 222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of shares as required by statute were voted in favor of the amendment.

 

THIRD: That said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

 

  State of Delaware
  Secretary of State
  Division of Corporations
  Delivered 05:32 PM 06/02/2022
  FILED 05:32PM06/02/2022
  SR 20222605008 - File Number 2296558

 

 

 

 

IN WITNESS WHEREOF, the Corporation has caused this certificate to be signed this 2nd day of June, 2022.

 

  By: /s/ Anthony Hayes
    Name:  Anthony Hayes
    Title: Chief Executive Officer

 

 

 

 

EX-99.1 3 ea161453ex99-1_aikido.htm PRESS RELEASE ANNOUNCING THE APPOINTMENT OF SOO YU TO THE AIKIDO INC., BOARD OF DIRECTORS

Exhibit 99.1

 

 

AIkido Pharma Inc. Appoints New Director, Soo Yu

 

New Director Supports NASDAQ Rule on Diversity

 

NEW YORK, NY June 10, 2022  /PRNewswire/ AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced the appointment of Ms. Soo Yu, as a director of the Company.

 

Anthony Hayes, CEO of Aikido stated, “At the time of the annual meeting, there was concern expressed by some shareholders about the Company’s compliance with the new NASDAQ rules on diversity. The Company strongly believes in diversity and Ms. Yu is an exceptional candidate that also satisfies the new NASDAQ rule. Further, Ms. Yu’s background broadens the experience and expertise of the Company, as we seek new areas of growth and opportunity for the Company. We welcome Ms. Yu and look forward to her involvement.”

 

About Soo Yu

 

Soo Yu is the Managing Director of International Private Client Services for Revere Securities. With more than a decade of experience working in financial services, she focuses on international business development and the cultivation of overseas client banking relationships. A naturalized U.S. citizen originally from South Korea, Soo brings significant expertise in Asian markets and expansive global reach through her connectivity with international contacts.

 

Soo earned her B.A. in Fine Arts from the Fashion Institute of Technology and studied at the University of Nottingham and the Paris Fashion Institute. She holds Series 7 and Series 66 designations and her real estate license. Previously, she maintained her Series 79 and 24 licenses.

Soo actively supports several nonprofit organizations, including philanthropies committed to improving the lives of children and the elderly as well as sustainability.

 

Further information about Ms. Yu’s appointment to the Board are provided in the Company’s Form 8-K which was filed on June 10, 2022 with the Securities and Exchange Commission.

 

About AIkido Pharma Inc.

 

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company's platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

 

 

 

 

Forward-Looking Statements

 

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

 

Contact:

 

Investor Relations: 

 

Hayden IR 
Brett Maas, Managing Partner 
Phone: (646) 536-7331 
Email: brett@haydenir.com 
www.haydenir.com

 

AIkido Pharma Inc. 
Phone: 212-745-1373 
Email: investorrelations@aikidopharma.com 
www.aikidopharma.com

 

 

 

 

EX-99.2 4 ea161453ex99-2_aikido.htm PRESS RELEASE ANNOUNCING THE REVERSE STOCK SPLIT OF AIKIDO INC. DATED JUNE 3, 2022

Exhibit 99.2

 

 

 

Aikido Announces Reverse Stock Split

  

New York, NY / June 3, 2022 / Aikido Pharma, Inc. (NASDAQ:AIKI), today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 17 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on June 7, 2022 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on June 7, 2022 under the Company’s existing trading symbol “AIKI”. At such time, the Company’s common stock will also commence trading under a new CUSIP number 0088753043.

 

We expect that the Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 20, 2022, will increase the market price per share of the Company’s common stock, bringing the Company into compliance with listing requirements for The Nasdaq Capital Market.

 

At the effective time of the Reverse Stock Split, every seventeen (17) shares of AIKI common stock issued and outstanding will be combined into one (1) share of common stock issued and outstanding, with no change to the par value of $0.0001 per share. This will reduce the Company’s outstanding common stock from approximately 89,294,446 million shares to approximately 5,252,555 million shares. Fractional shares resulting from the reverse stock split will be rounded down to the nearest whole share, and all currently issued shares of common stock held by a shareholder shall be aggregated for the purpose of determining whether the reverse stock split would result in the issuance of a fractional share. The shares and exercise prices, as applicable, underlying the Company’s outstanding equity awards and warrants will also be adjusted accordingly.

 

The Company’s transfer agent, Continental Stock Transfer & Trust Company (“Continental”) will provide stockholders of record holding certificates representing pre-split shares of the Company’s common stock as of the effective date, a letter of transmittal providing instructions for the exchange of shares. Registered stockholders holding pre-split shares of the Company’s common stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split, subject to such broker’s particular processes, and will not be required to take any action in connection with the Reverse Stock Split.

 

Additional information regarding the reverse stock split can be found in the Company’s definitive proxy statement (Form DEF 14A) filed with the U.S. Securities and Exchange Commission on April 12, 2022. Continental can be reached by phone at 917-262-2378

 

The Company does not anticipate raising any capital in the foreseeable future.

 

About AIkido Pharma Inc.

 

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company's platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

 

 

 

 

Cautionary Note on Forward-Looking Statements

 

This press release and any statements of stockholders, directors, employees, representatives and partners of Aikido Pharma, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the impact of the Reverse Stock Split described in this release) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

 

Contact:

 

Investor Relations:

 

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

 

AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

 

 

 

 

 

GRAPHIC 5 ex3-1_001.jpg GRAPHIC begin 644 ex3-1_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BB@\4 % M(2 "2< I7.1:V%L-TLQ'7 [*.['@5Q;6&L>-)F_MJ M;S;="=VG64YCLH",?+-,/FF8=U7Y1S0!U5YX\T6&Z>SL#<:O>H=K6^F1&RFWMS9VI=2WNQP-O;=C&2* ,TZ MMXSFM/.^W6 CSC-IHET\F<]@Y (]_2C^V/&D$,3_ &S3)%9L*+S2+J%V]F*D MJOUIUOXQBO;N]M8+G49KJU261XHWA!VQ2!'RH!*GG< >H%3R>*);>TCNU?4O MLES(HM9I%B9)U;=ABQV[ 0N<'KE>YH =!XPU^)U6XT&TU!6Z-I5^K/@=3Y4@ M5OR)K6TOQOH6IWBV)N)++4&&197\303?@K8S^&:E:*[O+**:ZT^VOD:,$)(@ MBF7/;!R ?Q%9>HZ+INJ6_P!AF0+D82RU1/,CS_L-G5/UH U**** "BBB@ KGO$_B>/0EMK.WB%WK%\2EG9[L;B.KN?X8UZEJUM M3U&UTC2[K4;V41VUM&TLCGL ,UY]H=C>:[JD^IZLGES7\ DO523>?A;B_12LM^2>(80.5@SP .7Z].3>U?5UB MTF=XK4&/3]GGV,<;&*UC(^8N%&)64')C!Q_.HM9UI2RSV\D,,T#HMM;RE8MD M9'W49N%E=<8!'RKZ$TZP@N;\R3R&Z19+G[0EG*GEQRRKUDP?G2+=U!^]C..< M4 5=/GUU]935+^P\N!8$B9)2L<:GL4)8J$92I(4%@PVYQUM#1]&U!+"R6SN= M1M$>Y>U#XB@VNV63)^8[>W';VK;M+FU6[4WH6>1,A91C9%@X.V/JBYP W?CG MI44=WNUIVC@GGC2XDFVPINQP(QST&2'- $D&C/IZ"9;/3HO+:23S)IW9E,GW MR6([UGWEH]UHJ*;2)=.M%\J#[):-*@N$N4E!6.>-=F6!YC=?X6/3\7T.H2'= M%=JJG;(@Y#$X"^:J$%U7G'/:@#HO#?B*V\2:8;F".2WGBU13J>H*3]Z*(_(G_ Y"!_P$UJBR M:WTNRL[HIYNHW.Z]+?Q,5+LO_CH3Z5S5FLNJ^/-8N67*OJ4-BO/2&WC\U_P, MCKQ[&M'QSJY@DCLF>**V4++*\J-\YW# 5A]P@;F##D$#MF@#7UO0-'G$U_/; M;)V4))) LDZ]!&6QG!X';/3I535X1<^$[^Y>YBC>0>9=>:"%4+UB..0!C&! MUY]:KO=ZA=WMM8%S)?:>AO8P0 M\@PJG/0'#'..C8/0TS4I&%M?S:FMQY=Q; MI,;.!0KH_F#RU'7+]B3QQZ"@"*QO[&P\.VQOS#Y6 MK=1L(VDD)/[M5;!!4< M8;LI&.U6GT72)YI9CJ=U;"&%8YU1_*8(3N"L1U^8GW&<9KSSQA%ITFG^'S;V MUZ1+J >5+PB12YCDW#T+;L\^Q(KF[F_M+6X>WN[O4[6U;:GEV\\@W =#MR%V M@\=2=^#S[#MZGFO/[JRA>^D6Z6'4S ?*CN)_WX=0!@_/GD=/J#3(8 M8Q<36UE T$SP,9([/]R?* ^8X7 QQVH ]::#2H],VQW4S2RP&%-<4LUFBWDY=V0BV"!D.W"]SQT' MX&@#U"WM;NYT>UN9FA?4HX\I(C9#@]5+#J&&,D?4=*C\-Z%I=AIL+6D8<8(5 MG4;@ 6 !QP6 )7=U(ZDUG:9!/A & M..RV&K2:>HBAT[[/#-;^;!;2/LV.K8D."/EC&0?ZU<;H3GO\IV_P# :L^# M;FYO+;4C?LSW/VI@YDB\MF0@%#M[*5(P/3KS6)8,ND^.](1$V+=0W&ERJ,8) MA/FQ'_O@L/QH ]#HHHH \T\#@2ZW$\@WNUSJT^]CSN^TK'^6T ?A6AJFEZCJ M'B&Y4,PEE4P@?:Q@6K<']WGU[XSGOVJAX('E:TBRG9(EUJT!0CDL;E9..V-I M'YUHW]BD/C&*2YO+*.YGG6:(D/YH1?E ) P!SCDX)]2: )-#ABM+R;1[J]BB MN8WS:) K#RS@%@K,-ISD$H.!Z5/XL6TT[06BE@2X>YE#237(9E!'5VV\\#H! M@?2H_%6CS0WD.KZ>EW).LJNT<;9C1@#^\:,_;G-8AN(=/DFMKB9O+.\0+MZ%AN"L5++W( . >:ZWXSS32/ID$=T'VZE' MB&)"KH/+?/S#V/8]QTKSX0760=]_]?-D]O?ZT 7])9M.1;:YN(8K=H_,A+$K MR6.1ECSV/'0D^U2ZGJ;6D$.H:?';ZE/:S!D@XD!9@RC(&> 2#COBLR/1KB\: M1UL9KF3;AGD&YNC8Y;ZT^;2I;,H?L=Q;3DMS$"A*8[E??UH U=/L_L&EI:Z? M$;66=]]_=M)M>X# [XS$!M5=Q&T=1CWKI_AW!:7VD>(;:;4YHR+V:1XPA98P MI1MWIVS^-< +>YW_P!:]*^"BROHNHVUS=1LCWEP&MG7]Z1E M1DD\D?XT =EX7AL[O1-MK)<1W$4[2EI8U22)W^;[HXVD'..>#ZU1\5R'3O+B MN)9I9;]1!)(TT$J?OH6BPVP;<@@\''O[8H /A_-<[; MR*YE$S.D4P=7W>6"NT1DX'(V^@Z^U5_%@,6NZ5+'M#1Z_:,,KG/F1LC?H!6I MX1O-2NKB\-ZDP1U64^;'MV2DMN1?8 #BLWQ8IEUG357DOKUDH^J(SM_XZ: . M^HHHH \XM6.D>/-:ADDVHNH07Z[CC,5Q'Y+8]0)%7^=:_BW3PLZWHFN6DNVB MLQ;PHA+_ #%@-S<#N:H^/;2*QU33-?E7;:2!M+U%\9"PRG]VY]DDVG/;<:Z2 MS\C7M&$5]'NEA;RKE-Q!25>&Y'KUX[&@"[I=_;ZC8I/;,VT#:RO]Y".H;WJY MBN3CO'A^P6=O)#I]K>%A$D2^9, ?NNQ.0 WJ1U(YS5J2[@L=398M5N+F2U"M M>6[ON"QOP&X& 01G'IF@#B_BQ',@@ >XR._X5YM9:A*GV;5["54FA/G1[EXR 058?B010!VK?#+42NX:I M:9_N>0Q!_'=_2G'X9W[_ #+JEO"#_ T!%=QB'0LO?]* /,]0L9=+U2>PGDBG M:+!$L.0&!]5/W2,$8KJ_A)!(EG?2;[0QO>7#!1S,,L!R?3@UQ&IW5U!?ZM<7 M;M/<+<,F<'_#%R]D+>T1%XS((@/7#'H<=^:B@O&U+ M4;D)K)MG64+!;IL.5P>2&');#'CL!63J2ZAJ]RK/-']D@&]8N]#O[C3]89C$M[YR#^_@^[!=J/3'ROCH>3TKTNN<\3^''U4 MP:CITL<&L6BLL+R+NCE1OOPRCNC8^H."* *\VD:DLT4%M;6DME&KB&83E9 K M?RK\3(XTZS@^6ZDW8+NV"65P?N\=^3BM7P MUXE@LX&LIX9;6&U;RKBWF;+Z**[G_P"/%G*B3^\R,/N[A][.!D\$&NXN9].T?PQ):6UJ&N8V51!* MV'$SM@2.W8;CDO\ EZ52TSQ8L\IL[Z*.\>V;=YH VC!(5U<\$'!P3@\=3QD M\SOM65;F2;60UA, $-O-&Z"'';G/KZ] *B@:WUN18].>2\?:?W5LA8N"1G\. MWIS7MKMI+1WJW-O)H7P>,=<$"FI_9-LUH]M:W4CVT?EQ".)E&W'' M7 />@#B/"GA"YFO;34]2ACN8BSKY$<@(@;IO9N[CH .GUZ=?K^JV^@:)):V: MR/Y"99(G'F; %P"Q#8 M(R#M/(Q6YJ^FZ/=V%M;[=:3:WFLRPW5O" MMP\ZY6XBC2*4-%(-JEF).%4\X '"@,:X[Q9XK6YCM[&QMY+ ML7;[;6U0X?4&!Z?[, ZLYZC@=: (/$>H7/B/4[?2-/9XI]0#Q0. UM: XFN M<_[8PB X]:]!L+&WTVPM[&TC$=M;QK%&@Z!0,"L7PGXWGO=2FCN=;OB' MO+A%PHQ]V-!V11P!]3WKHZ "BBB@ HHHH YOQ)X3BUJ:+4;*X;3];MD*V]]& MH;@]4D4\.A[J?PKEM/UZ^\+7B:;JUO%I+$A4C=B=/N.>L$O_ "R8_P#/-^/2 MO3:@N[.WOK:2VN[>*XMY!AXI4#*P]P: ,4ZCI6K%(;U)+*[Q\@G 5CG^X_*N M#[$@^E9=]X1F$5Z(1',UXR,\B(H(VLIQM/&TA I 8#':EG^'R6BL/#NJW.EQ ML$#VC0*GX$FM-/A[#?11Q^(=4N=4A0@K9H!;6JXZ#RH\9'^\30!CWF MOWWBB\:PT:&+56#;6*%O[/M6'>67CSS_ +"\<@ Z5-0 4444 %%% $% '_V0$! end GRAPHIC 6 ex3-1_002.jpg GRAPHIC begin 644 ex3-1_002.jpg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end GRAPHIC 7 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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ex99-2_001.jpg GRAPHIC begin 644 ex99-2_001.jpg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end EX-101.SCH 9 aiki-20220607.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 10 aiki-20220607_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 11 aiki-20220607_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
Jun. 07, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 07, 2022
Current Fiscal Year End Date --12-31
Entity File Number 000-05576
Entity Registrant Name AIKIDO PHARMA INC.
Entity Central Index Key 0000012239
Entity Tax Identification Number 52-0849320
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One One Rockefeller Plaza
Entity Address, Address Line Two 11th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10020
City Area Code 703
Local Phone Number 992-9325
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol AIKI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 13 ea161453-8k_aikido_htm.xml IDEA: XBRL DOCUMENT 0000012239 2022-06-07 2022-06-07 iso4217:USD shares iso4217:USD shares 0000012239 false --12-31 8-K 2022-06-07 AIKIDO PHARMA INC. DE 000-05576 52-0849320 One Rockefeller Plaza 11th Floor New York NY 10020 703 992-9325 false false false false false Common Stock, $0.0001 par value AIKI NASDAQ EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 15 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://aikidopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea161453-8k_aikido.htm aiki-20220607.xsd aiki-20220607_lab.xml aiki-20220607_pre.xml ea161453ex3-1_aikido.htm ea161453ex99-1_aikido.htm ea161453ex99-2_aikido.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 19 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea161453-8k_aikido.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea161453-8k_aikido.htm" ] }, "labelLink": { "local": [ "aiki-20220607_lab.xml" ] }, "presentationLink": { "local": [ "aiki-20220607_pre.xml" ] }, "schema": { "local": [ "aiki-20220607.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "AIKI", "nsuri": "http://aikidopharma.com/20220607", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea161453-8k_aikido.htm", "contextRef": "From2022-06-07to2022-06-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://aikidopharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea161453-8k_aikido.htm", "contextRef": "From2022-06-07to2022-06-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aikidopharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 20 0001213900-22-032242-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-032242-xbrl.zip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�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end